Immune System-Boosting Treatments Show Long-Sought Successes for Lung Cancer Patients

In the past 2 years, cancer treatments known as immune therapies have become all the rage. However, they have actually been explored for decades, particularly in melanoma, and have produced some notable successes. Now, immune therapies are showing more and more promise for lung cancer. Continue reading…

FDA Greenlights NSCLC Vaccine Trial for Subgroups

An experimental lung cancer vaccine does not extend life overall, but may still benefit some people, leading the U.S. Food and Drug Administration (FDA) to approve further trials for these groups. These findings were reported at the 2013 European Cancer Congress in Amsterdam, Netherlands. Called belagenpumatucel-L, the vaccine is based on non-small cell lung cancer (NSCLC) cell lines and boosts the immune response. The phase III clinical trial included 532 people with NSCLC who had already undergone chemotherapy and the vaccine benefitted two subgroups. People who had previously been treated with radiation lived longer (40 mo with radiation vs 10 mo without radiation), as did people whose lung cancers were not adenocarcinomas (20 mo for nonadenocarcinomas vs 12 mo for adenocarcinomas).